Flora Peyvandi/X
Apr 12, 2026, 13:26
Flora Peyvandi: What Can Be Alternative to Warfarin
Flora Peyvandi, Professor of Internal Medicine at the University of Milan and former President of ISTH, shared a post on X about a recent article by James H. Morrissey, published in ASH Publications:
“Warfarin may be more effective in high-thrombotic-risk conditions because it lowers prothrombin levels, a clotting protein with a long half-life (60–72 hours).
This long half-life helps smooth out fluctuations in drug effect over time.”
Title: A different alternative to warfarin?
Author: James H. Morrissey
Read the Full Article on ASH Publications
More posts featuring Flora Peyvandi on Hemostasis Today.
-
Oct 21, 2026, 00:58Anees Ur Rahman: Completing a Two-Week Clinical Rotation at Haemophilia Treatment Centre Rawalpindi
-
Oct 21, 2026, 00:56Caitlyn Mooney: Pulmonary Embolism in Athletes, Recognition and Return to Sport
-
Oct 21, 2026, 00:54Hani Karrar: Pleased to Share Our Review on Emicizumab in Hemophilia A Management
-
Oct 21, 2026, 00:53Akshay Sharma: HSCT Leads to Sustained Improvements in Sickle Cell Cardiomyopathy for Up to 3 Years
-
Oct 21, 2026, 00:51Prateek Meena: The F. A. T. R. N. Mnemonic for Recognizing TTP
-
Oct 20, 2026, 23:51Registration Is Open for WFH CCS 2027 – World Federation of Hemophilia
-
Oct 20, 2026, 23:44Edward Lee Carter: AF in Nursing Homes – When Stroke Risk Scores Tell Only Part of the Story
-
Oct 20, 2026, 22:59Building Effective Patient Advocacy Through Collaboration Between Patients and Clinicians – EHC
-
Oct 20, 2026, 21:22Intezar Mehdi: When Prolonged Bleeding May Indicate an Underlying Bleeding Disorder